FDA's Newest Testosterone Update | What Men Need to Know

The FDA has updated testosterone drug labeling to remove warnings about prostate cancer risk, based on extensive clinical evidence including the TRAVESE trial showing no difference in prostate cancer incidence between testosterone and placebo groups, reflecting decades of research demonstrating that testosterone does not cause or drive prostate cancer progression.